We report the case of a 28-year-old female We report the case of a 28-year-old female out-patient with bipolar disorder, whose out-patient with bipolar disorder, whose symptomatology was well-controlled with symptomatology was well-controlled with lithium carbonate 1200 mg (orally) lithium carbonate 1200 mg (orally) (0.9 mEq/l plasma levels) and risperidone (0.9 mEq/l plasma levels) and risperidone 1-2 mg (orally) daily. The patient had been 1-2 mg (orally) daily. The patient had been treated for several years in our department treated for several years in our department and the course of her illness was welland the course of her illness was wellknown; it showed that only lithium was known; it showed that only lithium was both effective and well-tolerated (topiraboth effective and well-tolerated (topiramate was not effective and carbamazepine mate was not effective and carbamazepine caused a rash) and only in coadministration caused a rash) and only in coadministration with low doses of risperidone. with low doses of risperidone.
However, the use of risperidone caused However, the use of risperidone caused a large increase in prolactin levels (above a large increase in prolactin levels (above 2000 2000 m mU/l, with normal values below U/l, with normal values below 500 500 m mU/l) and amenorrhoea (the rest of U/l) and amenorrhoea (the rest of the hormonal investigation and brain the hormonal investigation and brain magnetic resonance imaging were normal). magnetic resonance imaging were normal). The patient was put on 5 mg olanzapine The patient was put on 5 mg olanzapine (orally), but she did not tolerate this agent (orally), but she did not tolerate this agent because it made her feel 'confused' and because it made her feel 'confused' and 'tired'. She was then put on 200 mg quetia-'tired'. She was then put on 200 mg quetiapine (orally). Within 24 h the patient manipine (orally). Within 24 h the patient manifested diffuse muscle pains and headache. fested diffuse muscle pains and headache. She reported that her legs were stiff and She reported that her legs were stiff and she had pain in her knee joints. Neuroshe had pain in her knee joints. Neurological examination was normal, as were logical examination was normal, as were blood and biochemical tests including blood and biochemical tests including creatine phosphokinase. Vital signs were creatine phosphokinase. Vital signs were normal. No extrapyramidal signs or sympnormal. No extrapyramidal signs or symptoms (especially akathisia) were present. toms (especially akathisia) were present. The pain persisted for 5 more days and The pain persisted for 5 more days and the patient demanded that quetiapine be the patient demanded that quetiapine be discontinued. The pain disappeared within discontinued. The pain disappeared within the first 48 h of shifting back to risperidone, the first 48 h of shifting back to risperidone, which was according to the wishes of the which was according to the wishes of the patient. Six months passed and the patient patient. Six months passed and the patient is still free from symptoms. is still free from symptoms.
To our knowledge, this is the first reTo our knowledge, this is the first report of this kind of adverse effect related port of this kind of adverse effect related to quetiapine. Various other antipsychotics, to quetiapine. Various other antipsychotics, including haloperidol and olanzapine, are including haloperidol and olanzapine, are reported to cause muscle pain and rigidity reported to cause muscle pain and rigidity because of rhabdomyolysis, but the current because of rhabdomyolysis, but the current case had no laboratory or clinical findings case had no laboratory or clinical findings related to rhabdomyolysis. related to rhabdomyolysis. (2002) . The authors summarise treatment options for patients resistant to treatment options for patients resistant to clozapine monotherapy. However, in the clozapine monotherapy. However, in the section on combining antidepressants with section on combining antidepressants with clozapine, several issues deserve more clozapine, several issues deserve more attention. The authors disagree with utilattention. The authors disagree with utilisation of adjunctive antidepressants to isation of adjunctive antidepressants to reduce the cost of clozapine treatment. In reduce the cost of clozapine treatment. In our recent study (Lu our recent study (Lu et al et al, 2000) , addition , 2000), addition of 50 mg/day fluvoxamine to low-dose of 50 mg/day fluvoxamine to low-dose (100 mg/day) clozapine could raise the (100 mg/day) clozapine could raise the mean plasma clozapine level to over mean plasma clozapine level to over 400 ng/ml to achieve suitable therapeutic 400 ng/ml to achieve suitable therapeutic ranges. Therefore, concomitant fluvoxaranges. Therefore, concomitant fluvoxamine can reduce clozapine doses and, conmine can reduce clozapine doses and, consequently, costs (Armstrong & Cozza, sequently, costs (Armstrong & Cozza, 2001 ). 2001).
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Interestingly, this pharmacokinetic inInterestingly, this pharmacokinetic interaction is more pronounced in patients teraction is more pronounced in patients with high cytochrome P450 1A2 activity with high cytochrome P450 1A2 activity and at low clozapine plasma concentrations and at low clozapine plasma concentrations (Olesen & Linnet, 2000) . This phenomen- (Olesen & Linnet, 2000) . This phenomenon could therefore be used to narrow down on could therefore be used to narrow down the wide interindividual variation in blood the wide interindividual variation in blood . Norclozapine has been suggested to be more toxic than has been suggested to be more toxic than its parent compound. Although addition its parent compound. Although addition of fluvoxamine to low-dose clozapine was of fluvoxamine to low-dose clozapine was well-tolerated in our pilot study (Lu well-tolerated in our pilot study (Lu et al et al, , 2000) , further studies are warranted to 2000), further studies are warranted to substantiate its safety and efficacy. substantiate its safety and efficacy. Wetzel, H., Anghclescu, I., Szegedi, A., Wetzel, H., Anghclescu, I., Szegedi, A., et al et al (1998 Szegedi, A., et al et al ( ) (1998 Pharmacokinetic interactions of clozapine with selective Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. fluvoxamine and paroxetine in a prospective study.
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Olanzepine-induced tardive Olanzepine-induced tardive dyskinesia dyskinesia
Tardive dyskinesia is a serious and common Tardive dyskinesia is a serious and common motor side-effect of treatment with tramotor side-effect of treatment with traditional neuroleptics, with an unknown ditional neuroleptics, with an unknown pathophysiological basis. It affects 20-pathophysiological basis. It affects 20-30% of patients on long-term neuroleptic 30% of patients on long-term neuroleptic therapy, with elderly patients being at hightherapy, with elderly patients being at higher risk (American Psychiatric Association, er risk (American Psychiatric Association, 1994 ). 1994 .
Olanzapine is an atypical antipsychotic Olanzapine is an atypical antipsychotic agent with a reported lack of propensity to agent with a reported lack of propensity to cause tardive dyskinesia (Beasley cause tardive dyskinesia (Beasley et al et al, , 1999) . Recently, it has been suggested that 1999). Recently, it has been suggested that olanzapine can improve tardive dyskinesia olanzapine can improve tardive dyskinesia in some patients (Littrell in some patients (Littrell et al et al, 1998; Jaffe , 1998; Jaffe & Simpson, 1999) . Other authors, how-& Simpson, 1999) . Other authors, however, have shown that the prolonged ever, have shown that the prolonged use of olanzapine can instead be assouse of olanzapine can instead be associated with tardive dyskinesia/dystonia ciated with tardive dyskinesia/dystonia (Ananth & Kenan, 1999; Dunayevich & (Ananth & Kenan, 1999; Dunayevich & Strakowski, 1999) . Here we report the case Strakowski, 1999). Here we report the case of a patient who experienced tardive dyskiof a patient who experienced tardive dyskinesia after only few months of treatment nesia after only few months of treatment with olanzapine. with olanzapine.
A 62-year-old housewife with an A 62-year-old housewife with an unremarkable past medical history, sought unremarkable past medical history, sought out-patient treatment in June 2000 for out-patient treatment in June 2000 for anxiety, insomnia, difficulty thinking and anxiety, insomnia, difficulty thinking and concentrating, and frequent episodes of concentrating, and frequent episodes of aggressive behaviour. She was evaluated aggressive behaviour. She was evaluated by neurologists, and was submitted to by neurologists, and was submitted to routine biochemical investigations (unroutine biochemical investigations (unremarkable), a computerised tomography remarkable), a computerised tomography scan (normal), and the Mini-Mental State scan (normal), and the Mini-Mental State Examination (24/30). Olanzapine (10 mg/ Examination (24/30). Olanzapine (10 mg/ day) was started and this was the sole day) was started and this was the sole medication continued thereafter. The medication continued thereafter. The patient soon experienced a subjective patient soon experienced a subjective improvement. Three to four months later improvement. Three to four months later she noticed slight involuntary movements she noticed slight involuntary movements of the tongue and jaw. Despite these of the tongue and jaw. Despite these symptoms, she continued taking olanzasymptoms, she continued taking olanzapine until it was eventually stopped 1.5 pine until it was eventually stopped 1.5 years later (December 2001 
